HGP0608

DRUG4 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

HealthyHyperlipidemiaHypertensionHypertension(HTN)

Phase 1

Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405

CompletedNCT02387554

Hanmi Pharmaceutical Company LimitedHypertension(HTN)

Start: 2014-08-31End: 2014-10-31Updated: 2015-06-12

A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.

CompletedNCT04081844

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2018-05-03End: 2018-06-28Updated: 2019-09-09

A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.

CompletedNCT04322266

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2018-12-21End: 2019-02-13Updated: 2020-03-26

Phase 3

Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia

CompletedNCT02899455

Hanmi Pharmaceutical Company LimitedHyperlipidemia, Hypertension

Start: 2014-07-31End: 2016-06-30Updated: 2016-10-20

Related Papers

Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual Components in Healthy Participants.

2024-05-22

Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study

Drug Design Development and Therapy2020-12-0125 citations

A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia

Clinical Therapeutics2017-11-1422 citations